Inhibace Plus

Quick links to important sections

Inhibace Plus

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Inhibace Plus

Quick Facts

Property Description
Active Ingredients Cilazapril, Hydrochlorothiazide (HCTZ)
Form Oral Film-coated Tablet
Pharmacological Class ACE Inhibitor and Thiazide Diuretic Combination
General Purpose Management of High Blood Pressure (Hypertension)
Origin Synthetic

What Type of Medicine is Inhibace Plus?

Inhibace Plus is a prescription-only, synthetic medicinal product formulated as a fixed-dose combination (FDC) antihypertensive agent. It is presented as an oral film-coated tablet and contains two separate active ingredients: Cilazapril and Hydrochlorothiazide (HCTZ). The FDC format is clinically recognized for enhancing consistency in the long-term control of essential hypertension. This formulation is a popular combination, with similar FDCs sometimes marketed under names such as Vascace Plus or generic alternatives like APO-Cilazapril/HCTZ.


How is Inhibace Plus Composed and Classified?

This medication combines two distinct pharmacological classes to target blood pressure through complementary mechanisms. Cilazapril is classified as an Angiotensin-Converting Enzyme (ACE) inhibitor, which functions as a prodrug that is metabolized in the body to its active compound, Cilazaprilat. The second component, Hydrochlorothiazide, is a specific thiazide diuretic. This combination is well-established in clinical practice as an effective strategy for controlling elevated blood pressure. The finished tablet, designed for oral administration, is manufactured using these two active ingredients along with inert excipients necessary for the tablet's stability and form.


What is the General Purpose of the Dual-Action Combination?

The general purpose of this dual-component system is to leverage a powerful and reliable synergistic antihypertensive effect. This therapeutic strategy is often applied to adult patients whose blood pressure is not adequately managed with a single antihypertensive agent alone. The combination provides control by addressing two separate physiological systems: Cilazapril promotes vasorelaxation (vessel widening), while Hydrochlorothiazide contributes to fluid volume reduction via increased salt and water excretion. The collective result is a sustained decrease in pressure against artery walls, which is the core benefit for patients with hypertension.

Regulatory References

  1. Hydrochlorothiazide: MedlinePlus Drug Information

What side effects are possible with Inhibace Plus?

Possible side effects and safety information

The official safety profile for Inhibace Plus, a combination of Cilazapril and Hydrochlorothiazide (HCTZ), classifies potential adverse reactions based on their reported frequency and the body system affected, according to regulatory standards.

Frequency-Classified Adverse Reactions

Classification Examples of Reactions
Common Headache, dizziness, fatigue, persistent dry cough, nausea, and abdominal pain.
Uncommon Signs of hypotension (low blood pressure), rash, itching, muscle cramps, and sleep disturbance.
Rare/Very Rare Severe skin reactions, hepatic failure/jaundice, and acute renal failure.

Serious Adverse Reactions officially documented include Angioedema (rapid swelling of the face, tongue, or throat, which can be life-threatening) and Pancreatitis.

Population and Duration Safety Notes

The combination is contraindicated during the second and third trimesters of pregnancy due to the established risk of fetal injury. Safety and efficacy have not been established in children and adolescents. Use is not recommended in patients with severe renal impairment.

Some effects, such as hypotension and dizziness, are noted as being more likely to occur following the initial dose or during dose escalation. Long-term use of the Hydrochlorothiazide component is associated with an elevated risk of Non-melanoma skin cancer. Furthermore, the combination is contraindicated in individuals with a history of angioedema related to previous ACE inhibitor therapy or severe hepatic impairment.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for an Inhibace Plus (Cilazapril/Hydrochlorothiazide) overdose is defined by the risks stemming from both its active components, primarily severe hypotension and critical electrolyte imbalance.


Documented Manifestations and Severe Outcomes

Overdose may present with severe Hypotension and its associated effects, including Dizziness, Tachycardia or Bradycardia, and Palpitations. Serious documented outcomes include the potential for Circulatory Shock and Acute Renal Failure. The thiazide component may also lead to significant Electrolyte Disturbances (e.g., Hyponatremia, Hyperkalemia). An acute, serious reaction related to the hydrochlorothiazide component, Acute Angle-Closure Glaucoma, requires urgent attention.


Emergency Actions and Management

In the event of a suspected overdose, regulators mandate that individuals contact a regional Poison Control Center or emergency services immediately. Immediate medical attention is required for all suspected cases.

No specific antidote is known for this medication. Management is therefore confined to Symptomatic and Supportive Treatment. Procedural measures described to limit absorption include Gastric Lavage or administration of Activated Charcoal. Management often involves Volume Expansion using normal saline infusion to correct severe hypotension. A specific consideration exists for Patients with Severe Liver Disease, as the thiazide component carries the risk of precipitating Hepatic Coma following over-exposure.

Therapeutic Uses of Inhibace Plus

Quick Facts

Condition Use and Benefit
High Blood Pressure An established treatment option for managing essential hypertension
Inadequate Blood Pressure Control May be used when blood pressure is not sufficiently managed by a single agent

Inhibace Plus is an approved pharmacological combination used in the management of high blood pressure, also known as essential hypertension. It is typically considered for individuals whose condition is not adequately controlled with therapy using only the single active component, cilazapril. This medication is a component of a comprehensive approach to help maintain blood pressure within a desirable range.

The use of this combination may be a convenient factor in the ongoing management of this chronic health condition, providing a fixed dosage for two necessary therapeutic agents. Controlling high blood pressure is a key factor in supporting overall cardiovascular health and reducing related health risks.

Eligibility and Restrictions for Use

Inhibace Plus (cilazapril and hydrochlorothiazide) is an authorized prescription medicine, and its use is subject to specific regulatory eligibility rules. It must not be used by certain patient populations or those with specific medical conditions, as defined in official product labeling.

Absolute Contraindications Restricted/Non-Recommended Groups
History of Angioedema (swelling) from any ACE inhibitor therapy. Pregnancy: Contraindicated in the second and third trimesters.
Known Hypersensitivity to cilazapril, hydrochlorothiazide, other ACE inhibitors, or sulfonamide-derived drugs. Breastfeeding: Use is not recommended.
Anuria (inability to produce urine). Pediatric Population: Not recommended for children/adolescents under 18 years; safety is not established.
Severe Renal Impairment (creatinine clearance <30 mL/min). Severe Liver Cirrhosis: Use requires great caution and careful titration.
Concomitant use with sacubitril/valsartan or Aliskiren in patients with diabetes or moderate-to-severe renal impairment. Older Adults (Geriatrics): May require close monitoring or dose adjustment.

Eligibility is defined by excluding these high-risk groups. Patients should also not take this medicine if they have specific metabolic disorders, such as hereditary galactose intolerance, due to an excipient (lactose) in the formulation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes documented interactions based on official government regulatory information for Inhibace Plus (cilazapril and hydrochlorothiazide).


Contraindicated and Restricted Combinations

Co-administration with Neprilysin Inhibitors (e.g., sacubitril/valsartan) is forbidden due to the risk of angioedema. A minimum 36-hour separation period is required when switching between these agents. Use with Aliskiren is restricted in patients with diabetes or moderate-to-severe kidney impairment, as this combination significantly increases the risk of serious side effects like hyperkalemia and decreased kidney function.

Clinically Significant Interactions

Interacting Agent Category Mechanism and Constraint
Potassium-Elevating Agents (Potassium supplements, salt substitutes, potassium-sparing diuretics) The cilazapril component may cause hyperkalemia; concomitant use is officially not recommended.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) May reduce the blood pressure-lowering effect of Inhibace Plus and increase the risk of worsening kidney function, particularly in volume-depleted patients.
Lithium The combination with both components can increase lithium levels, requiring careful monitoring.
Antidiabetic Agents Requires close blood glucose monitoring due to the potential for the two components to affect blood sugar levels in opposing ways.

Food and Timing Requirements

To ensure proper absorption of the hydrochlorothiazide component, Inhibace Plus must be administered at least 4 hours before or 4 to 6 hours after the ingestion of bile acid sequestrants such as cholestyramine or colestipol.

Mechanism of Action

How Inhibace Plus Works

Inhibace Plus is a combination product where its pharmacodynamic actions arise from two distinct, additive mechanisms: trandolapril (an ACE inhibitor) and verapamil (a calcium channel blocker).


Modulating the Renin-Angiotensin System

Trandolapril functions by inhibiting the angiotensin-converting enzyme (ACE), thereby preventing the conversion of angiotensin I to the vasoconstrictor angiotensin II. This inhibition interrupts the signaling cascade, leading to reduced peripheral resistance and a decrease in circulating volume, modifying the resulting physiological responses related to tissue fluid dynamics and vascular tone.


Influencing Vascular and Cardiac Calcium Flux

Verapamil acts by blocking the influx of extracellular calcium ions through voltage-sensitive L-type calcium channels in the myocardium and vascular smooth muscle. This mechanism limits calcium-mediated contractility and depolarization, contributing to a diminished chronotropic and inotropic effect in cardiac tissue and a reduction in vascular smooth muscle tone.


Dual-Pathway Hemodynamic Adjustment

The combined effect involves simultaneous, non-overlapping modulation of two major regulatory systems: the renin-angiotensin system and calcium-dependent cellular signaling. The two mechanisms integrate to influence systemic hemodynamic parameters, including vascular resistance and cardiac output, through independent yet additive physiological pathways.

Dosage and Administration Information

Administration Protocol: Usage Guidelines

Inhibace Plus (cilazapril and hydrochlorothiazide) is an oral film-coated tablet that is used according to a standardized protocol for the maintenance phase of hypertension treatment.


Dosing Schedule and Method

The standard prescribed regimen is one tablet of the fixed-dose combination (typically 5 mg cilazapril and 12.5 mg hydrochlorothiazide) once daily. This medication is not indicated for starting therapy, but rather for patients whose individual component doses have been established and correspond to the fixed combination strength.

For consistent administration, the dose should be taken at about the same time each day, preferably in the morning. The tablet may be taken with or without food, as food intake does not have a clinically significant effect on absorption.


Procedural Instructions

The tablets must be swallowed whole with a glass of water and must not be crushed or chewed.

If a dose is missed, instructions advise to skip the missed dose and continue with the next scheduled dose at the regular time; a double dose must not be taken to compensate.


Population-Specific Constraints

The use of Inhibace Plus is not recommended for children and adolescents under 18 years of age because safety and efficacy have not been established in this population. Furthermore, it is not recommended for use in patients with severe renal impairment (creatinine clearance < 30 mL/min) due to the thiazide diuretic component.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Inhibace Plus

This overview summarizes the clinical research and evidence base for the cilazapril/hydrochlorothiazide combination, adhering strictly to official regulatory reports and scientific literature. This summary describes what the research has explored, what findings were observed, and where uncertainty remains, without offering medical advice or treatment recommendations.


Evidence for Use in Essential Hypertension

Research on this combination was studied for the management of high blood pressure (essential hypertension). The core evidence is based on randomized controlled trials (RCTs) conducted in adults whose condition was inadequately controlled by taking only the single active component, cilazapril. The studies primarily monitored short-term outcomes monitoring physiological strain or stress, such as Sitting Systolic and Diastolic Blood Pressure (SSBP/SDBP) readings. Findings describe patterns observed in the studies where measurements of blood pressure readings differed between the combination group and the single-component therapy or placebo groups. The research does not predict whether an individual will respond similarly to the group findings.


Research Outcomes and Limitations

The main outcomes used in the primary trials were surrogate endpoints (blood pressure measures) rather than long-term major cardiovascular outcomes like preventing a heart attack or stroke. The research is limited in evaluating data related to major health events. Most efficacy trials were conducted over limited follow-up durations, typically weeks to a few months.

While the combination was evaluated in subgroups of older adults, data for certain groups remain insufficient. For instance, the research does not fully establish the evidence base for use in patients with certain serious pre-existing comorbidities. The research highlights what is known — and what is still uncertain—regarding the full clinical utility of this combination.

Key Studies & References

  1. PRODUCT MONOGRAPH Pr APO-CILAZAPRIL/HCTZ (Health Canada - Cilazapril and Hydrochlorothiazide)

Frequently Asked Questions (FAQ)

Common questions about Inhibace Plus (FAQ)


Q: What is the main difference between Inhibace and Inhibace Plus?

A: Inhibace contains only one active ingredient, cilazapril, which is an Angiotensin-Converting Enzyme (ACE) inhibitor. In contrast, Inhibace Plus is a fixed-dose combination product containing both cilazapril and hydrochlorothiazide, a type of diuretic.


Q: Why is a diuretic combined with an ACE inhibitor in Inhibace Plus?

A: The combination is used to help manage blood pressure through two distinct mechanisms. Regulatory documents describe that the ACE inhibitor works by relaxing blood vessels, while the diuretic helps reduce fluid volume by increasing the excretion of salt and water, contributing to a synergistic effect.


Q: What kind of research has been done on Inhibace Plus?

A: Studies on the combination product were generally conducted in adult patients whose high blood pressure was not controlled enough by taking the single component, cilazapril, alone. Official information indicates that, unlike the single component, the combination of cilazapril and hydrochlorothiazide does not show evident differences in blood pressure response between Black and non-Black patients.


Q: Does Inhibace Plus interact with common pain relievers like ibuprofen?

A: Ibuprofen belongs to the class of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Official documents note that NSAIDs may reduce the blood pressure-lowering effect of the drug and increase the risk of worsening kidney function, especially in volume-depleted (dehydrated) patients.


Q: How does the ACE inhibitor component of Inhibace Plus work?

A: The cilazapril component is converted in the body into its active form, cilazaprilat. This active form works by blocking the Angiotensin-Converting Enzyme (ACE), which prevents the production of angiotensin II, a hormone that narrows blood vessels. This results in the blood vessels relaxing, helping to lower blood pressure.


Q: Does the diuretic component of Inhibace Plus cause increased urination?

A: The hydrochlorothiazide component is a diuretic, or 'water pill.' Its function is to promote the removal of excess salt and water from the body through the kidneys, which results in an increased flow of urine.


Q: Does Inhibace Plus have any restrictions regarding alcohol consumption?

A: Official labeling notes that consuming alcohol may change or modify the effect of this medication. Due to this, official patient information notes that limiting alcohol consumption is suggested during treatment.


Q: How quickly does Inhibace Plus usually start to affect blood pressure?

A: Regulatory information indicates that the blood pressure-lowering effect from the cilazapril component is typically observed within the first hour after taking a dose. The medication generally reaches its greatest effect between three and seven hours after administration.


Q: Is it common to feel dizzy when first starting Inhibace Plus?

A: Dizziness is listed as a common possible side effect in the official safety profile. The possibility of low blood pressure (hypotension) is noted as being more likely to occur immediately following the initial dose or when the dosage is adjusted.


Q: Can Inhibace Plus make me feel tired or lethargic?

A: Official safety information for the medication lists fatigue and general unusual tiredness as common possible side effects.


Q: Is Inhibace Plus used for conditions other than high blood pressure?

A: The combination product, Inhibace Plus, is officially indicated for the management of high blood pressure (hypertension). However, the single component, cilazapril, is indicated for the treatment of congestive heart failure in some regulatory areas.


Q: Are there different strengths of Inhibace Plus available?

A: Regulatory databases confirm that this fixed-dose combination is available in several strengths. For example, one common strength contains 5 mg of cilazapril and 12.5 mg of hydrochlorothiazide, among others.


Q: Is it okay to drive or operate machinery while taking Inhibace Plus?

A: Because the medication may cause side effects like dizziness or fatigue, official information indicates that individuals should use caution when performing activities that require alertness, such as driving vehicles or operating machinery.


Q: Does Inhibace Plus affect my sleep?

A: Official safety information lists sleep disturbance or general sleeping problems as uncommon possible side effects of the medication.


Q: What are the possible interactions between Inhibace Plus and herbal supplements?

A: Specific contraindications for all herbal supplements are not universally listed on drug labels. Official information suggests that many herbal supplements and natural health products may interact with blood pressure medications, and patients discuss the use of herbal supplements with a healthcare provider.


Q: Is there a link between Inhibace Plus and feeling dehydrated?

A: Since the medication is a diuretic that increases water excretion, regulatory warnings indicate that minimizing the risk of dehydration is important when taking this medication.


Q: Can Inhibace Plus cause changes to one's sense of taste?

A: Official safety information lists that the medication may cause an altered sense of taste or a change in the way things taste as a possible side effect.


Q: What does the research say about Inhibace Plus in different ethnic groups?

A: Official product information notes that the generally lower blood pressure response often seen when ACE inhibitors are used alone in Black patients is no longer evident when cilazapril is combined with the diuretic hydrochlorothiazide.


Q: Can Inhibace Plus be used by people with a history of gout?

A: The medication contains a thiazide diuretic (hydrochlorothiazide), which has been recognized as a substance that may be associated with an increased risk of gout or elevated uric acid levels. Although a history of gout is not always an absolute contraindication, patients with this medical history are typically noted as requiring careful monitoring.


Q: Does Inhibace Plus cause sun sensitivity or skin reactions?

A: Official safety information states that the medication may cause increased sensitivity to light (photosensitivity) and notes that protection from UV rays, such as from sunlight or tanning lamps, is recommended for patients.


Q: What are the reported effects of Inhibace Plus on electrolyte balance?

A: The medication is known to influence the body's electrolyte balance. The cilazapril component may lead to hyperkalemia (high potassium), while the hydrochlorothiazide component is associated with a risk of hypokalemia (low potassium) and other electrolyte disturbances.

How should Inhibace Plus be stored and disposed of?

How to Store and Dispose of Inhibace Plus?

Inhibace Plus (cilazapril and hydrochlorothiazide) tablets must be managed according to specific regulatory requirements to maintain product stability and safety.

Storage Requirements

The medication should be stored at room temperature, typically defined as 20 C to 25 C (68 F to 77 F). It must be kept in its closed container in a dry place and protected from light and moisture. To prevent accidental ingestion, the tablets must always be stored out of the reach and sight of children.


Official Disposal Instructions

Unused or expired tablets must not be disposed of in wastewater (down the sink or toilet) or in household garbage. Patients must ask a pharmacist for the proper method on how to dispose of the medication safely and in accordance with local environmental regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Inhibace Plus found in:

A-Z Index: